Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid pharmacokinetics and safety in primary biliary cholangitis with moderate to severe hepatic impairment
2017-001762-13Phase 4Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Obeticholic acid with Placebo (2 arms). Started Jun 2018; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2017-001762-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001762-13.